周二,欧洲股市在圣诞节前夕缩短的交易时段收高。斯托克600指数上涨0.2%,科技股领涨,此前美国同行周一表现强劲。伦敦富时100指数和法国CAC 40指数也收涨。诺和诺德股价飙升5.7%,从上周CagriSema减肥药试验结果令人失望后的暴跌中恢复过来。在监管机构反馈后,阿斯利康撤回了其在欧盟的癌症治疗申请,股价收盘上涨0.1%。矿业股推动以英美资源集团为首的斯托克600指数上涨2%,尽管智利因涉嫌环境违规而面临170亿美元的潜在罚款。有关中国计划在2025年创纪录发行国债的报道支持了市场情绪。另一方面,由于年终延迟,Vistry Group下调了利润预测,下跌了16%,而瑞典博彩公司Evolution在监管审查中继续下滑。
European markets ended higher on Tuesday in a shortened session ahead of Christmas Eve. The Stoxx 600 rose 0.2%, with tech stocks leading gains after a strong performance by US peers on Monday. London's FTSE 100 and France's CAC 40 also closed in positive territory. Novo Nordisk surged 5.7%, recovering from last week’s slump following disappointing trial results for its CagriSema weight-loss drug. AstraZeneca withdrew its EU application for a lung cancer treatment after feedback from regulators, with shares closing up 0.1%. Mining stocks boosted the Stoxx 600, led by Anglo American, up 2%, despite facing $17 billion in potential fines in Chile over alleged environmental violations. Reports of China’s planned record treasury bond issuance in 2025 supported sentiment. At the other end, Vistry Group dropped 16% after revising profit forecasts downward due to year-end delays, while Swedish gambling firm Evolution continued its slide amid regulatory scrutiny.